NCT00792350已完成不适用
International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 791
- 主要终点
- Efficacy: status of tumor, patients performance status
研究概览
简要总结
In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the duration of Sorafenib treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In- and outpatients with diagnosis of hepatocellular carcinoma (HCC) and decision taken by the investigator to prescribe Nexavar
排除标准
- •Exclusion criteria must be read in conjunction with the local product information
研究组 & 干预措施
Group 1
干预措施: Sorafenib (Nexavar, BAY43-9006) (Drug)
结局指标
主要结局
Efficacy: status of tumor, patients performance status
时间窗: At each follow-up visit, every 2-4 months
次要结局
- Duration of treatment(At each follow-up visit, every 2-4 months)
- Time of survival(At each follow-up visit, every 2-4 months)
- Reports of adverse events(At each follow-up visit, every 2-4 months)
研究者
相似试验
已完成
不适用
Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in SurgeryHemophilia ANCT00922597Bayer26
已完成
4 期
Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb IschemiaLower Limb IschemiaNCT02369809Human Stem Cell Institute, Russia210
撤回
不适用
Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney CancerCarcinoma, Renal CellNCT01353794Bayer
已完成
不适用
Surveillance Study of NovoRapid® for New Drug Re-examinationDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT01490112Novo Nordisk A/S1,239
已完成
4 期
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)Chronic Kidney DiseaseRenal InsufficiencyNCT00908310GE Healthcare213